Special Interest Satellite Symposium 02: the role of digital imaging in HPV-based cervical cancer screening programes 

11:45 – 13:15 EDT (​GMT-4)

Chair:

Nomonde H. Mbatani

Presentations:

• What are the critical research questions to realise the potential of digital imaging in cervical cancer screening?
  Louise Kuhn
• Results of digital screening in South African women participating in a cervical cancer screen and treat study
  Silvia de Sanjosé
• Implementation challenges of automated visual evaluationin cervical cancer screening programmes
  Delivette Castor
• What are artificial intelligence and machine learning? What can biomedical engineering offer in the cervical cancer screening space?
  Tinashe Mutsvangwa

Special Interest Satellite Symposium 04: HPV prevention, screening and treatment approaches for people living with HIV

7:15 AM – 8:15 AM EDT (​GMT-4)

Chairs:

Elisabeth McClymont

Joel Palefsky

Presentations:

• Epidemiology of HPV in people living with HIV
  Silvia Franceschi
• HPV vaccination for women living with HIV
  Elisabeth McClymont
• HPV screening for women living with HIV
  Silvia de Sanjosé
• HPV cervical treatment for women living with HIV
  Kimon Chatzistamatiou
• HPV anal screening, vaccination and treatment for men living with HIV
  Joel Palefsky

Special Interest Satellite Symposium 05: Global HPV laboratory network

7:15 AM – 8:15 AM EDT (​GMT-4)

Chairs:

Joakim Dillner

Suzanne Garland

Presentations:

• Role of reference laboratory to further HPV elimination
  Suzanne Garland
• Global HPV proficiency studies
  Camilla Lagheden
• National reference laboratory re-analysis of HPV-negative HSIL as means to further testing quality
  Jean-Luc Prétet
• Electronic HPV laboratory manual
  Elizabeth R Unger
• Key performance indicators of HPV-based screening
  Maria Dolores Fellner

Special Interest Satellite Symposium 07: HPV vaccine introduction in LMIC: key factors in global and national-level decision-making, implementation lessons learned and evidence for one-dose use

7:00 – 8:00 AM EDT (​GMT-4)

Chairs:

Rupali Limaye

Alex Vorsters

Presentations:

• Global-level challenges to HPV vaccine introduction and decision-making
  Dominique Guillaume
• National-level changes to HPV vaccine introduction and decision-making
  Dur-e-Nayab Waheed
• Implementation lessons learned from HPV vaccine introduction in Kenya
  Nelly Mugo
• Evidence related to HPV vaccine one-dose schedule from trials conducted in Tanzania, Costa Rica and India
  Deborah Watson-Jones
• Advocacy and social mobilization efforts for cervical cancer screening, pre-cancer treatment, and HPV vaccine introduction in India
  Neerja Bhatla

Special Interest Satellite Symposium 08: International Indigenous HPV Alliance for the Elimination of Cervical Cancer for Indigenous Peoples

7:00 – 8:00 AM EDT (​GMT-4)

Chairs:

Bev Lawton

Lisa Whop

Presentations:

• He patu te ware te whare tangata (the sacred house of hummanity): exploring HPV self-testing to address inequities in cervical cancer for Maori in Aotearoa New Zealand.
  Anna Adcock, Bev Lawton
• Addressing inequities: HPV self-sampling and vaccination programmes for aboriginal and Torres Strait islander peoples.
  Lisa Whop, Anni Morseu-Diop
• Working towards elimination of Stbbis, including HPV, as well as addressing health inequities and achieving wellness by, with and for First Nations, Métis and Inuit
  Alexandra King

Special Interest Satellite Symposium 09: New guidelines for validation of HPV Assays usable in cervical cancer screening

9:45 – 10:45 AM EDT (​GMT-4)

Chairs:

Marc Arbyn

Mario Poljack

Presentations:

• Welcome
  Suzanne Garland
• Analytical Criteria for Validation of the Genotyping Capacity of HPV Tests
  Joakin Dillner
• Validation of HPV point-of-care tests
  Maribel Almonte
• FDA Principles for Validation of HPV Assays in the USA, FDA Principles
• Nicolas Wentzensen
• New clinical validation guidelines and challenges of the 5th instalment of VALGENT
  Marc Arbyn

Special Interest Satellite Symposium 10: What is needed to implement screen and treat using HPV DNA testing in low and well resourced settings?

14:00 – 15:30 EDT (​GMT-4)

Chair:

Silvia de Sanjosé

Presentations:

• Improving sensitivity and specificity of point of care HPV testing in Cape Town
  Louise Kuhn
• What are the programmatic parameters critical to successful implementation of screen and treat strategies using point of care HPV DNA testing in a primary care setting
  Rakiya Saidu
• Evaluation of point of care HPV DNA testing in Papua Nueva Guinea – what have we learned?
  Diep Nguyen
• Is HPV DNA testing for cervical cancer screening feasible in Mozambique?
  Kathleen Schmeler 

Special Interest Satellite Symposium 11: Blood-based screening approaches for HPV-associated head and neck cancers

14:00 – 15:30 EDT (​GMT-4)

Chair:

Daniel Faden

Presentations:

• ctDNA for the detection of HPV-associated head and neck cancers
  Daniel Faden
• HPV E6 antibodies and risk of HPV-associated head and neck cancer
  Hilary Robbins
• Prospective screening for early detection of HPV-associated head and neck cancer
  Tim Waterboer

Special Interest Satellite Symposium 12: Clinical, biological and epidemiologic evidence for latency and their implications

14:00 – 15:30 PM EDT (​GMT-4)

Chairs:

Anna-Barbara Moscicki

Anne Hammer

Presentations:

• Basic science of latency
  Ignacio Bravo
• How does reactivation affect models of cancer risk
  Nicole Campos
• Epidemiology of latency
  Anne Rositch
• Clinical: implications for care
  Anne Hammer

Special Interest Satellite Symposium 13: HPV-Based Self-Collection for Cervix Screening: Implementation Lessons and Future Directions

14:00 – 15:30 PM EDT (​GMT-4)

Chairs:

Laurie Smith (Canada)
Sharon Hanley (Japan)

Presentations:

• HPV-Based Self-Collection for Cervix Screening: Implementation Lessons and Future Directions in British Columbia and Canada
  Gina Ogilvie (Canada)

• Canadian Women’s Attitudes and Preferences for Self-Sampling
  Zeev Rosenberg (Canada)

• Cervical Screening for Physically Disabled Women and People with A Cervix
  Susan Sherman (UK)

• HPV-Based Self-Collection for Cervix Screening: Implementation Lessons and Future Directions in Uganda
  Carolyn Nakisige (Uganda)

• Preparing for The Equitable Introduction of HPV Self-sampling in Aotearoa New Zealand
  Collette Bromhead (New Zealand)

• HPV-Based Self-Collection for Cervix Screening: Implementation Lessons and Future Directions in Australia
  Marion Seville (Australia)

Special Interest Satellite Symposium 14: Current evidence for safety profile of the HPV vaccines

17:15 – 18:45 AM EDT (​GMT-4)

Chairs:

Aimée R. Kreimer (USA)

Toshiyuki Sasagawa (Japan)

Background. Hundreds of millions of HPV vaccine doses have been administered globally. Post-marketing surveillance studies have confirmed initial observations in clinical trials of a strong safety record. Yet, concerns regarding the safety of the HPV vaccines continue to impede their use.

Learning Objectives. The main objective of this session is to understand the status of the safety data for HPV vaccines, and the different sources used to generate these data. Participants will learn to interpret results from safety analyses, and to discern true signals of concern from anecdotes and scare tactics. The specific objectives are to review and understand:

• Different sources of vaccine adverse event data, and the methodologic approaches used for analyzing the data;
• Rigorously collected and interpreted safety data from the USA, Australia and globally.
• Safety concerns regarding HPV vaccination in Japan; and,
• Distinguishing true safety concerns from anti-vaccine misinformation and appropriate messaging of vaccine safety data.

Presentations:

• Introduction to HPV Vaccine Monitoring
  Suzanne Garland (Australia)
• Vaccine Safety Monitoring by the WHO: approaches and results
  Paul Bloem (Switzerland)
• Vaccine Safety Monitoring in the USA: Approaches and Results
  Lauri Markowitz (USA)
• Vaccine Safety Monitoring in Australia: Approaches and Results                                       Kristine Macartney (Australia)
• Scientific Evaluation of Alleged Findings in HPV Vaccines in Japan
  Ikuo Tsunoda (Japan)
• Messaging HPV vaccine safety
  Alex Vorsters (Belgium)
• Discussion
  Toshiyuki Sasagawa (Japan)

Special Interest Satellite Symposium 15: HPV integration, gene expression and carcinogenesis 

14:30 – 16:00 PM EDT (​GMT-4)

Chairs:

Zhi-Ming Zheng

Alison McBride

Presentations:

• HPV integration/oropharyngeal cancer
  Maura L. Gillison
• Decoding HPV integration/long-read sequencing 
  Yan Lu
• DNA looping/HPV integration and expression
  Ian J. Groves
• Selective expression of HPV integration sites and clonal expansion
  Lulu Yu

Special Interest Satellite Symposium 15: Anogenital HPV infection in pharmacologically immunosuppressed patients 

On Demand

Moderator:

Andreia Albuquerque

Mayura Nathan

Presentations:

• Introduction
  Mayura Nathan
• Cervix
  Kimon Chatzistamatiou
• Vulva and vagina
  Pedro Vieira Baptista
• Anus
  Andreia Albuquerque
• Penis
  Mayura Nathan

Special Interest Satellite Symposium 18: HPV among transgender and gender diverse individuals: understanding the unique needs of the population

On Demand

Moderator:

Sarah Jackson

Alison Berner

Presentations:

• Anal cancer screening among transgender people with HIV
  Joel Palefsky
• Urinary HPV testing for transgender individuals
  Elmar Joura 
• Knowledge, attitudes, and perceived risks of HPV among transgender women in Pakistan
  Muslima Ejaz
• HPV prevalence and vaccination among transwoman in the Condesa Study
  Jorge Salmeron

Special Interest Satellite Symposium 14: Key Issues in HPV Cancer Elimination In Europe: Challenges and opportunities:

On Demand

Moderator:

Anne Hammer

Patti Gravitt

Presentations:

• Histopathological classification of CIN2
  David Jenkins
• Active surveillance vs excisional treatment – where are we?
  Kathrine Dyhr Lycke
• Risk stratification of CIN2 for clinical management
  Anne Hammer
• Risks and benefits of active surveillance vs excisional treatment
  Ilkka Kalliala